SCHEMBL263217

SCHEMBL263217

COC(C)COc1ccccc1Br

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
MEN1 O00255 2/20 0.53
GAA P10253 1/20 0.53
ATM Q13315 1/20 0.53
HTR7 P34969 1/20 0.49
RAB9A P51151 5/20 0.44
NPC1 O15118 4/20 0.44
MAPT P10636 3/20 0.44
L3MBTL1 Q9Y468 3/20 0.44
CYP1A2 P05177 2/20 0.44
HPGD P15428 2/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
POLB P06746 1/20 0.42
LMNA P02545 3/20 0.41
AGTR1 P30556 1/20 0.40
GRM4 Q14833 1/20 0.39
HTR1A P08908 1/20 0.38
ADRA2A P08913 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7694021 0.85 KMT2A (0.49) KMT2ASMN1; SMN2MEN1GAAATM
SCHEMBL29671577 0.84 KMT2A (0.59) KMT2ASMN1; SMN2MEN1GAAATM
SCHEMBL6468101 0.84 KMT2A (0.59) KMT2ASMN1; SMN2MEN1GAAATM
SCHEMBL262863 0.81 PKM (0.50) KMT2ASMN1; SMN2MEN1GAAATM
SCHEMBL5362727 0.81 KMT2A (0.53) KMT2ASMN1; SMN2MEN1GAAATM
SCHEMBL16180345 0.81 KMT2A (0.53) KMT2ASMN1; SMN2MEN1GAAATM
SCHEMBL5362724 0.81 KMT2A (0.53) KMT2ASMN1; SMN2MEN1GAAATM
SCHEMBL1496589 0.81 KMT2A (0.60) KMT2ASMN1; SMN2MEN1GAAATM
SCHEMBL11565366 0.81 KMT2A (0.53) KMT2ASMN1; SMN2MEN1GAAATM
SCHEMBL11455939 0.79 ALDH1A1 (0.55) SMN1; SMN2GAAMAPTCYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2183241-B1 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LTD (GB) 2012-12-19 EP disclosed
US-8134007-B2 Pyridine derivatives PFIZER INC. (US) 2012-03-13 US disclosed
EP-2183241-A2 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS Pfizer Limited (GB) 2010-05-12 EP disclosed
CN-101675040-A 2-pyridinecarboxamide derivatives as sodium channel modulators PFIZER LTD 2010-03-17 CN disclosed
US-20090048306-A1 PYRIDINE DERIVATIVES PFIZER, INC. (US) 2009-02-19 US disclosed
WO-2008135826-A2 2 -PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LIMITED (GB) 2008-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048306-A1 PYRIDINE DERIVATIVES SDHA, P2RX4, P2RX3 KMT2A 4299/4885SMN1; SMN2 765/4885MEN1 3487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.